TY - JOUR
T1 - Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma
T2 - An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
AU - Avivi, Irit
AU - Montoto, Silvia
AU - Canals, Carme
AU - Maertens, John
AU - Al-Ali, Haifa
AU - Mufti, Ghulam J.
AU - Finke, Jürgen
AU - Schattenberg, Anton
AU - Fanin, Renato
AU - Cornelissen, Jan J.
AU - Vernant, Jean Paul
AU - Russell, Nigell
AU - Beguin, Yves
AU - Thomson, Kirsty
AU - Verdonck, Leo F.
AU - Kobbe, Guido
AU - Tilly, Herve
AU - Socié, Gerard
AU - Sureda, Anna
PY - 2009/12
Y1 - 2009/12
N2 - Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the outcome of patients with FL treated with MUD-SCT included in the European Group for Blood and Marrow Transplantation registry. 131 patients treated with reduced-intensity conditioning (RIC, n = 87) or conventional myeloablative (CONV, n = 44) MUD-SCT between 2000 and 2005 were included. Median time from diagnosis to MUD-SCT was 47 months and the median number of previous therapeutic regimens was 4 (previous autograft: 47%). RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) was 24% and 30% at 100-d and 1-year, respectively. After a median follow-up of 36 months, 17% of the patients developed disease progression, the 3-year progression-free survival (PFS) being 47%. Three-year overall survival (OS) for the whole series was 51%. On multivariate analysis, RIC regimens were associated with at lower NRM and a significantly longer PFS and OS. This retrospective study demonstrated that MUD-SCT results, even in heavily pre-treated populations, in a meaningful PFS and OS.
AB - Matched unrelated donor stem cell transplantation (MUD-SCT) provides the only curative option for patients with follicular lymphoma (FL) who fail conventional therapies and do not have a sibling donor. The purpose of this study was to analyse the outcome of patients with FL treated with MUD-SCT included in the European Group for Blood and Marrow Transplantation registry. 131 patients treated with reduced-intensity conditioning (RIC, n = 87) or conventional myeloablative (CONV, n = 44) MUD-SCT between 2000 and 2005 were included. Median time from diagnosis to MUD-SCT was 47 months and the median number of previous therapeutic regimens was 4 (previous autograft: 47%). RIC recipients were significantly older, with a longer interval from diagnosis to MUD-SCT and had failed a previous autograft more frequently than CONV recipients. Non-relapse mortality (NRM) was 24% and 30% at 100-d and 1-year, respectively. After a median follow-up of 36 months, 17% of the patients developed disease progression, the 3-year progression-free survival (PFS) being 47%. Three-year overall survival (OS) for the whole series was 51%. On multivariate analysis, RIC regimens were associated with at lower NRM and a significantly longer PFS and OS. This retrospective study demonstrated that MUD-SCT results, even in heavily pre-treated populations, in a meaningful PFS and OS.
KW - Conditioning regimen
KW - Follicular lymphoma
KW - Matched unrelated donor transplant
UR - http://www.scopus.com/inward/record.url?scp=70449401609&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2009.07905.x
DO - 10.1111/j.1365-2141.2009.07905.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 19793383
AN - SCOPUS:70449401609
SN - 0007-1048
VL - 147
SP - 719
EP - 728
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -